Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06104774
Other study ID # d17573
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 20, 2023
Est. completion date July 31, 2025

Study information

Verified date October 2023
Source China Medical University Hospital
Contact Hsin-Yuan Fang, Ph.D
Phone 04-22052121
Email fanghy@cmuh.org.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To explore the effect of a family-centered, eight-week, progressive sit-to-stand Tai Chi exercise on lung function and mental health in patients after thoracoscopic surgery_


Description:

Lung cancer is the top death among cancers in Taiwan. The surgical excision of lung tissue is unable to regenerate new tissue after thoracoscopic lobectomy, resulting in decreased lung function and affecting health-related quality of life. 29% of female patients who received thoracic surgery tended to be anxious and depressed, and more than 60% of the family caregivers experienced mild to moderate caregiving burden and anxiety. Tai Chi exercise is a gentle exercise that can effectively enhance lung function. However, there is a lack of literature on the effects of Tai Chi exercise on lung function and mental health after thoracoscopic surgery.Methods: Exploratory sequential mixed methods study design will be used. The first phase will be a quasi-experimental study that will use purposive sampling to recruit thoracoscopic surgical patients and their family caregivers. It is estimated to enroll 60 pairs of patients and their family caregivers. The participants will be divided into experimental and control groups according to the sequential time of admission. The experimental group will receive Tai Chi exercise and routine treatment after the operation, and after discharge from the hospital, they will perform Tai Chi exercise three times a week, 50 minutes each time, for a total of eight weeks after discharge; the control group will receive conventional treatment. Repeated measures analysis of variance (repeated ANOVA) will be used for comparison between the experimental group and the control group and within the group; for other confounding factors, generalized estimating equations (GEE) will be used for analysis. In the second stage, after eight weeks of Tai Chi exercise, semi-structured interviews with about 10 patients and their caregivers will be conducted to collect their experiences and feelings related to the Tai Chi exercise. Qualitative data will be used to comprehend the quantitative data.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date July 31, 2025
Est. primary completion date July 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Hospitalized to receive thoracoscopic lobectomy, wedge/partial resection, lobectomy, or sleeve resection. 2. American Society of Anesthesiologists (ASA) physiological status classification I-II (ASA, 2019).ASA Physical Status Class I: A healthy person who is healthy and does not smoke or drink.ASA physical status class II: People with mild chronic diseases but no substantial functional limitations. 3. Those who can walk on their own without any impairment in limb movement. 4. Able to communicate in Chinese or Taiwanese. Exclusion Criteria: 1. Individuals requiring chemotherapy and radiation therapy for malignant tumors. 2. Those who have practiced Tai Chi, Qigong, external elixir exercises, or pulmonary exercises within the past year. 3. Anticipating hospitalization or surgical treatment within the next three months. 4. Individuals with musculoskeletal or peripheral vascular diseases. 5. Individuals with visual impairment, intellectual disabilities, or memory loss.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Tai Chi Exercise
The experimental group will receive Tai Chi exercise and routine treatment after the operation, and after discharge from the hospital, they will perform Tai Chi exercise three times a week, 50 minutes each time, for a total of eight weeks after discharge.

Locations

Country Name City State
Taiwan China Medical University Taichung North Dist.

Sponsors (1)

Lead Sponsor Collaborator
China Medical University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary vital capacity (VC) data will be collected through lung function test admission day, discharge 1 day, 7 day after discharge, one month after discharge, two months after discharge
Primary forced vital capacity (FVC) data will be collected through lung function test admission day, discharge 1 day, 7 day after discharge, one month after discharge, two months after discharge
Primary forced expiratory volume in one second (FEV1) data will be collected through lung function test admission day, discharge 1 day, 7 day after discharge, one month after discharge, two months after discharge
Secondary Hospital anxiety and depression scale composite This scale measures the feelings of anxiety and stress that one has experienced in the past week. It has a total of 14 questions, including 7 questions each for the Anxiety Scale (HADS-A) and the Depression Scale (HADS-D). It is measured on a 4-point Likert scale. Score method (0-3), the total score of each item is 0-21 points, the higher the score measured by the scale, the higher the degree of anxiety and depression. The Cronbach's a coefficients of the internal consistency reliability of HADS-A and HADS-D are respectively 0.82-0.74, with high internal consistency. Baseline (Before operation), immediately post-operation, discharged 1 day, one week after discharge, one month after discharge, two months after discharge
See also
  Status Clinical Trial Phase
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Completed NCT02909452 - Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Phase 1
Completed NCT04741958 - Role of Ultrasound Guided Peripheral Thoracic Tumors N/A
Recruiting NCT04556344 - Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer N/A
Terminated NCT03306693 - Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers N/A
Completed NCT04751552 - Erector Spinae Block for Thoracoscopic Surgery N/A
Completed NCT05770869 - mHealth ALIBIRD: A Digital Health Care Model N/A
Active, not recruiting NCT04589247 - Improving Cancer Symptom Management
Not yet recruiting NCT04133337 - Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC Phase 1/Phase 2
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Completed NCT02188563 - A Comprehensive Smoking Cessation Intervention Duration Radiation for Upper Aerodigestive Cancers N/A
Completed NCT03134872 - A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC Phase 3
Not yet recruiting NCT04371796 - Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC Phase 2
Completed NCT00437372 - Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients Phase 1
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04862780 - (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC Phase 1/Phase 2
Recruiting NCT04776447 - Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) Phase 2
Recruiting NCT05988736 - Comparison Between McGrath and Macintosh Laryngoscopes for DLT Intubation in Thoracic Surgery Patients. N/A
Not yet recruiting NCT06376084 - Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
Active, not recruiting NCT04222972 - A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Phase 3